Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,521.20
(
-0.08%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
106.85
(
-0.21%
)
Bitcoin
68,936.00
(
0.11%
)
News Focus
News Focus
Post# of 447197
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Pharmacydude

Send PM Follow Ignore
Followers 45
Posts 1535
Boards Moderated 0
Alias Born 11/25/2013

Pharmacydude

Re: oneragman post# 358338

Thursday, 10/28/2021 9:14:10 PM

Thursday, October 28, 2021 9:14:10 PM

Post# of 447197
One
Another possibility is that ECLA was making too high a demand for royalties WRT patents.
ECLA owns the study and the data. Maybe they had an agreement with Amarin on allowing Amarin to use their data from PI2 in their patent applications but ECLA wanted to increase their royalties for any data from PI3 and Amarin decided to pass.
Just a thought
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News